Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
Lipella Pharmaceuticals Inc. (OTC : LIPO) Stock
MWN-AI** Summary
MWN-AI** Analysis
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Description
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Quote
| Last: | $0.08 |
|---|---|
| Change Percent: | 0.0% |
| Open: | $0.0798 |
| Close: | $0.08 |
| High: | $0.0905 |
| Low: | $0.0798 |
| Volume: | 64,867 |
| Last Trade Date Time: | 06/18/2026 01:07:56 pm |
Stock Data
| Market Cap: | $1,122,494 |
|---|---|
| Float: | 4,574,629 |
| Insiders Ownership: | N/A |
| Institutions: | 6 |
| Short Percent: | 66935% |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | www.lipella.com |
| Country: | US |
| City: | Pittsburgh |
Recent News Releases
Subscribe to Our Newsletter
Message Board Posts
**MWN-AI FAQ is based on asking OpenAI questions about Lipella Pharmaceuticals Inc. (OTC: LIPO).


